Table 3.

Effect of anagrelide treatment on megakaryocyte ploidy in essential thrombocythemia

2N4N8N16N32N64N128N
Controls (n = 18) 10.7 ± 3.03-150 6.5 ± 1.4 12.5 ± 3.4 45.9 ± 3.4 23.7 ± 5.4 < 1  
Patients (n = 10)        
 Before treatment 7.6 ± 3.0 5.3 ± 2.7 10.2 ± 3.3 25.5 ± 4.1 35.7 ± 5.4 13.4 ± 4.8 2.3 ± 0.7 
 After treatment 10.6 ± 2.2 7.5 ± 1.7 13.4 ± 2.7 33.5 ± 3.7 27.8 ± 2.7 6.9 ± 3.6 0.3 ± 0.3 
2N4N8N16N32N64N128N
Controls (n = 18) 10.7 ± 3.03-150 6.5 ± 1.4 12.5 ± 3.4 45.9 ± 3.4 23.7 ± 5.4 < 1  
Patients (n = 10)        
 Before treatment 7.6 ± 3.0 5.3 ± 2.7 10.2 ± 3.3 25.5 ± 4.1 35.7 ± 5.4 13.4 ± 4.8 2.3 ± 0.7 
 After treatment 10.6 ± 2.2 7.5 ± 1.7 13.4 ± 2.7 33.5 ± 3.7 27.8 ± 2.7 6.9 ± 3.6 0.3 ± 0.3 
F3-150

Percent of total.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal